Movetis wins two out of three categories at the PharmaVentures European Deals 2010 Awards
Movetis NV announced that it has won the European Financing Deal of the Year and the European M&A Deal of the Year at the PharmaVentures European Deals 2010 Awards. The awards recognise Movetis’ successful IPO on Euronext Brussels in December 2009, as well as the recent public tender offer by Shire on all outstanding shares and warrants of Movetis. These prestigious awards were presented yesterday night at the Sachs Associates 10th Annual Biotech in Europe Investor Forum in Zurich.
These awards reflect the rapid development and success of Movetis before and since its IPO in 2009. In October last year the Company gained the authorisation to market Resolor for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief in 30 European countries. This was followed by Movetis’ successful IPO on Euronext Brussels in December 2009 and the commercial launch of Resolor in the first European markets in the first half of 2010. In August 2010, Switzerland became the 31st country where Resolor is approved in a first indication.
Other news from the department business & finance
